Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

A Research Study to See How a New Weekly Insulin, Insulin Icodec When Given Along With Semaglutide Helps in Reducing the Blood Sugar Level in Patients With Type 2 Diabetes

← catalyst calendar

NCT05813912 · results posted

Sponsored by Novo Nordisk A/S (industry) · NVO — their whole pipeline →.

Phase
Phase 3
Status
Completed
Study type
Interventional
Design
Na · None · Treatment
Enrollment
148actual
Sites
39
Countries
Czechia, Malaysia, Poland +2

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2023-09-22actualWhen the study began enrolling
Primary completion2025-04-14actualThe date the last participant is measured for the primary outcome — the readout window
Study completion2025-05-16actualThe whole study's end, after follow-up
First posted2023-04-14actualWhen this record first appeared on the registry
Results posted2026-06-03actualWhen the sponsor posted results to the registry
Record updated2026-06-03actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

  • Diabetes Mellitus, Type 2

Interventions

  • Drug: Insulin Icodec
  • Drug: Semaglutide

Primary outcome

what the primary-completion date above is the date OF
Change in Glycated Haemoglobin (HbA1c)
measured Baseline (Week 26), Week 52

Posted documents

hosted by the registry — we link, never re-serve
Study Protocolposted 2024-08-28 · 1.3 MB · Prot_000.pdf
Statistical Analysis Planposted 2023-09-12 · 454 KB · SAP_001.pdf

Publications

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · NVO's whole pipeline · Catalyst calendar · Every registered study · What changed